Apellis Pharmaceuticals Inc

APLS.US
Healthcare · Biotechnology
Price N/A
USD · NASDAQ

Company Information

Company Name
Apellis Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US03753U1060
CIK: 0001492242
CUSIP: 03753U106
Currency: USD
Full Time Employees: 733
Phone: 617 977 5700
Fiscal Year End: December
IPO Date: Nov 09, 2017
Description:

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.

Address:

100 Fifth Avenue, Waltham, MA, United States, 02451

People

Directors & Officers

Name Title Year Born
Dr. Cedric Francois M.D., Ph.D. Co-Founder, President, CEO & Director 1972
Mr. Alec Machiels J.D., MBA Co-Founder & Director 1973
Mr. Timothy E. Sullivan CFO & Treasurer 1971
Mr. David O. Watson Esq., J.D. General Counsel & Secretary 1973
Ms. Kelley Boucher Chief People Officer NA
Dr. Caroline R. Baumal M.D. Chief Medical Officer 1968
Dr. Pascal Deschatelets Ph.D. Co-Founder & Chief Scientific Officer 1970
Mr. James G. Chopas CPA VP, Corporate Controller & Chief Accounting Officer 1967
Ms. Eva Stroynowski Head of Investor Relations NA
Prof. Peter Hillmen M.D., Ph.D. Head of Hematology Engagement & Member of PNH Scientific Advisory Board NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 11, 2026 Mark Jeffrey Delong N/A Sale 368.00 $22.15 $8.15K
Jan 22, 2026 Caroline Baumal N/A Sale 2.80K $21.77 $60.89K
Jan 22, 2026 Timothy Eugene Sullivan N/A Sale 10.29K $21.77 $223.95K
Jan 22, 2026 Pascal Deschatelets N/A Sale 5.93K $21.77 $129.05K
Jan 22, 2026 Nur Nicholson N/A Sale 7.73K $21.77 $168.17K
Jan 22, 2026 Mark Jeffrey Delong N/A Sale 3.37K $21.77 $73.39K
Jan 22, 2026 James George Chopas N/A Sale 2.06K $21.77 $44.93K
Jan 22, 2026 David O Watson N/A Sale 7.83K $21.77 $170.50K
Jan 22, 2026 Cedric Francois N/A Sale 27.19K $21.77 $591.97K
Jan 20, 2026 Caroline Baumal N/A Sale 1.88K $19.79 $37.24K
Jan 20, 2026 Cedric Francois N/A Sale 8.18K $19.79 $161.92K
Jan 20, 2026 David O Watson N/A Sale 2.48K $19.79 $48.98K
Jan 20, 2026 James George Chopas N/A Sale 726.00 $19.79 $14.37K
Jan 20, 2026 Mark Jeffrey Delong N/A Sale 1.33K $19.79 $26.40K
Jan 20, 2026 Nur Nicholson N/A Sale 2.20K $19.79 $43.60K
Jan 20, 2026 Pascal Deschatelets N/A Sale 909.00 $19.79 $17.99K
Jan 20, 2026 Timothy Eugene Sullivan N/A Sale 2.89K $19.79 $57.23K
Jan 13, 2026 Timothy Eugene Sullivan N/A Sale 3.86K $22.19 $85.56K
Jan 13, 2026 Pascal Deschatelets N/A Sale 2.28K $22.19 $50.53K
Jan 13, 2026 Nur Nicholson N/A Sale 2.62K $22.19 $58.09K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 13.54M Mar 31, 2026 10.57% $0.01 116.24%
venBio Select Advisor LLC 12.22M Mar 31, 2026 9.55% $4.84 0.00%
Vanguard Group Inc 10.67M Dec 31, 2025 8.34% $0.00 6.88%
Morgan Stanley - Brokerage Accounts 10.04M Mar 31, 2026 7.84% $0.02 9.48%
State Street Corp 6.84M Mar 31, 2026 5.35% $0.01 48.37%
UBS Group AG 6.21M Mar 31, 2026 4.85% $0.04 48.26%
Vanguard Portfolio Management, LLC 5.40M Mar 31, 2026 4.22% $0.01 0.00%
Pentwater Capital Management LP 5.25M Mar 31, 2026 4.10% $1.10 0.00%
Vanguard Capital Management, LLC 4.77M Mar 31, 2026 3.73% $0.00 0.00%
Deep Track Capital, LP 4.53M Mar 31, 2026 3.54% $2.98 -41.52%
Point72 Asset Management, L.P. 4.18M Mar 31, 2026 3.27% $0.22 600.04%
RTW INVESTMENTS, LLC 3.69M Mar 31, 2026 2.88% $1.48 -51.93%
HBK INVESTMENTS L P 3.55M Mar 31, 2026 2.77% $1.45 0.00%
Suvretta Capital Management, LLC 3.52M Mar 31, 2026 2.75% $3.62 -15.00%
Millennium Management LLC 2.26M Mar 31, 2026 1.76% $0.04 138.45%
Geode Capital Management, LLC 2.08M Mar 31, 2026 1.62% $0.01 2.44%
JPMorgan Chase & Co 2.05M Mar 31, 2026 1.60% $0.00 1,198.18%
The Goldman Sachs Group Inc 1.98M Mar 31, 2026 1.55% $0.01 946.56%
Balyasny Asset Management LLC 1.92M Mar 31, 2026 1.50% $0.10 2,843.98%
Dimensional Fund Advisors, Inc. 1.34M Mar 31, 2026 1.05% $0.01 640.08%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Ossiam Lux-OssiamSerenityErCITSTF1CURAcc 505.00K 0.39% ▲ 0.00% Oct 31, 2025
2 International Biotechnology Ord 412.73K 0.32% ▼ 18.48% Mar 31, 2026
3 Man Event Driven Alternative IN USD 386.47K 0.30% ▲ 0.00% Mar 31, 2026
4 Pictet Biopharmaceutical Mother 347.71K 0.27% ▲ 13.91% Oct 14, 2025
5 Russell 1000 Index Non-Lendable Fund B 337.94K 0.26% ▲ 0.00% Dec 31, 2025
6 Russell 1000 Index Non-Lendable Fund 337.94K 0.26% ▲ 0.00% Dec 31, 2025
7 Fidelity Global Equity+ Fund - F8 337.91K 0.26% ▲ 0.00% Mar 31, 2026
8 Fidelity NorthStar Sr F 300.00K 0.23% ▲ 0.00% Mar 31, 2026
9 First Trust Merger Arbitrage Cl I 299.78K 0.23% ▲ 0.00% Mar 31, 2026
10 Extended Equity Market Fund E 257.01K 0.20% ▲ 0.00% Dec 31, 2025

Financial Highlights

Market Cap: $5.25B
EBITDA: $166.62M
P/E Ratio: $38.35
Book Value: $3.24
Earnings/Share: $1.07
Profit Margin: 12.06%
Operating Margin: 9.87%
ROA (TTM): 10.93%
ROE (TTM): 46.02%
Revenue (TTM): $1.11B
Revenue/Share (TTM): $8.72
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 60.90%

Valuation Metrics

Enterprise Value: $5.32B
Trailing P/E: 38.35
Forward P/E: 46.30

Shares Statistics

Shares Outstanding: 128.02M
Shares Float: 83.22M
% Insiders: 1,136.50%
% Institutions: 11,042.80%
Short % Float: 12.55%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$1.00B
Cost of Goods Sold
adjust
$-102.24M
Gross Profit
subtotal
$901.55M
SG&A
adjust
$-550.27M
R&D
adjust
$-295.85M
Operating Income
subtotal
$55.43M
Other / Non-Operating Items
adjust
$-33.04M
Net Income
subtotal
$22.39M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about APLS.US!